Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Gaucher Disease | 8 | 2020 | 15 | 1.460 |
Why?
|
| Vitiligo | 1 | 2019 | 8 | 0.640 |
Why?
|
| Leukoencephalopathies | 1 | 2019 | 14 | 0.640 |
Why?
|
| Autoimmune Diseases of the Nervous System | 1 | 2019 | 9 | 0.640 |
Why?
|
| Nervous System Malformations | 1 | 2019 | 18 | 0.630 |
Why?
|
| Alopecia | 1 | 2019 | 37 | 0.620 |
Why?
|
| Thrombocytopenia | 1 | 2019 | 84 | 0.600 |
Why?
|
| Autoimmune Diseases | 1 | 2019 | 81 | 0.600 |
Why?
|
| Enzyme Replacement Therapy | 6 | 2017 | 17 | 0.590 |
Why?
|
| Glucosylceramidase | 5 | 2017 | 8 | 0.580 |
Why?
|
| Lymph Nodes | 1 | 2014 | 258 | 0.410 |
Why?
|
| Pyrrolidines | 3 | 2017 | 67 | 0.370 |
Why?
|
| Lung | 1 | 2014 | 507 | 0.360 |
Why?
|
| Enzyme Inhibitors | 3 | 2017 | 378 | 0.330 |
Why?
|
| Brain | 1 | 2014 | 1311 | 0.270 |
Why?
|
| Glucosylceramides | 2 | 2017 | 4 | 0.260 |
Why?
|
| Chromosomes, Human, Pair 10 | 1 | 2025 | 4 | 0.250 |
Why?
|
| Chromosome Deletion | 1 | 2025 | 140 | 0.230 |
Why?
|
| Abnormalities, Multiple | 2 | 2016 | 167 | 0.230 |
Why?
|
| Phenotype | 4 | 2025 | 732 | 0.190 |
Why?
|
| Spleen | 3 | 2017 | 170 | 0.170 |
Why?
|
| Intellectual Disability | 2 | 2025 | 128 | 0.170 |
Why?
|
| Adolescent | 5 | 2019 | 6459 | 0.170 |
Why?
|
| Monoclonal Gammopathy of Undetermined Significance | 1 | 2020 | 112 | 0.170 |
Why?
|
| Potassium Channels | 1 | 2018 | 33 | 0.160 |
Why?
|
| Lysosomes | 1 | 2018 | 86 | 0.150 |
Why?
|
| Neurodegenerative Diseases | 1 | 2018 | 75 | 0.150 |
Why?
|
| Autophagy | 1 | 2018 | 167 | 0.140 |
Why?
|
| Complement System Proteins | 1 | 2017 | 31 | 0.140 |
Why?
|
| Female | 13 | 2025 | 26829 | 0.140 |
Why?
|
| Point Mutation | 1 | 2016 | 65 | 0.130 |
Why?
|
| Humans | 16 | 2025 | 50201 | 0.130 |
Why?
|
| Vesicular Transport Proteins | 1 | 2016 | 40 | 0.130 |
Why?
|
| Vestibular Diseases | 1 | 2015 | 8 | 0.130 |
Why?
|
| Recombinant Proteins | 1 | 2017 | 480 | 0.130 |
Why?
|
| Hematologic Diseases | 1 | 2015 | 21 | 0.120 |
Why?
|
| Face | 1 | 2015 | 58 | 0.120 |
Why?
|
| Liver | 3 | 2017 | 1122 | 0.120 |
Why?
|
| Male | 11 | 2025 | 25572 | 0.120 |
Why?
|
| Psychosine | 1 | 2014 | 1 | 0.120 |
Why?
|
| Glycosphingolipids | 1 | 2014 | 3 | 0.120 |
Why?
|
| B-Lymphocytes | 1 | 2015 | 175 | 0.120 |
Why?
|
| Longevity | 1 | 2014 | 79 | 0.110 |
Why?
|
| Seizures | 1 | 2016 | 195 | 0.110 |
Why?
|
| Hair Diseases | 1 | 2013 | 8 | 0.110 |
Why?
|
| Lipids | 1 | 2014 | 147 | 0.110 |
Why?
|
| Genes, ras | 1 | 2013 | 43 | 0.110 |
Why?
|
| Short Bowel Syndrome | 1 | 2013 | 16 | 0.110 |
Why?
|
| Hair | 1 | 2013 | 29 | 0.110 |
Why?
|
| Hyperammonemia | 1 | 2013 | 23 | 0.110 |
Why?
|
| ras Proteins | 1 | 2013 | 64 | 0.110 |
Why?
|
| Neoplasm Proteins | 1 | 2015 | 321 | 0.110 |
Why?
|
| Follow-Up Studies | 2 | 2017 | 2188 | 0.110 |
Why?
|
| Inflammation | 1 | 2017 | 608 | 0.100 |
Why?
|
| DNA-Binding Proteins | 1 | 2015 | 424 | 0.100 |
Why?
|
| Nervous System Diseases | 1 | 2013 | 88 | 0.100 |
Why?
|
| Macrophages | 1 | 2014 | 362 | 0.100 |
Why?
|
| Disease Progression | 1 | 2014 | 821 | 0.100 |
Why?
|
| Child | 6 | 2025 | 6862 | 0.090 |
Why?
|
| Child, Preschool | 4 | 2025 | 3896 | 0.090 |
Why?
|
| Glycogen Storage Disease Type IV | 1 | 2010 | 1 | 0.090 |
Why?
|
| Glycogen Debranching Enzyme System | 1 | 2010 | 2 | 0.090 |
Why?
|
| Sequence Deletion | 1 | 2010 | 69 | 0.080 |
Why?
|
| Mutation, Missense | 1 | 2010 | 104 | 0.080 |
Why?
|
| Platelet Count | 2 | 2017 | 74 | 0.070 |
Why?
|
| Multiple Myeloma | 1 | 2020 | 2934 | 0.060 |
Why?
|
| Mutation | 3 | 2018 | 1288 | 0.060 |
Why?
|
| Infusions, Intravenous | 2 | 2016 | 213 | 0.060 |
Why?
|
| Musculoskeletal Abnormalities | 1 | 2025 | 14 | 0.060 |
Why?
|
| Musculoskeletal Diseases | 1 | 2025 | 47 | 0.060 |
Why?
|
| Pedigree | 2 | 2018 | 125 | 0.060 |
Why?
|
| Administration, Oral | 2 | 2017 | 432 | 0.060 |
Why?
|
| DNA Copy Number Variations | 1 | 2025 | 109 | 0.060 |
Why?
|
| Adult | 5 | 2020 | 13486 | 0.060 |
Why?
|
| Developmental Disabilities | 1 | 2025 | 119 | 0.060 |
Why?
|
| Young Adult | 3 | 2020 | 4052 | 0.060 |
Why?
|
| Infant | 3 | 2018 | 3584 | 0.050 |
Why?
|
| Brazil | 1 | 2020 | 35 | 0.050 |
Why?
|
| Severity of Illness Index | 2 | 2016 | 959 | 0.040 |
Why?
|
| Middle Aged | 3 | 2020 | 12356 | 0.040 |
Why?
|
| Age of Onset | 1 | 2018 | 108 | 0.040 |
Why?
|
| United States | 2 | 2020 | 4898 | 0.040 |
Why?
|
| Splenectomy | 1 | 2017 | 34 | 0.040 |
Why?
|
| Complement C5a | 1 | 2017 | 4 | 0.040 |
Why?
|
| Saccharomyces cerevisiae Proteins | 1 | 2018 | 142 | 0.040 |
Why?
|
| Glucosyltransferases | 1 | 2017 | 6 | 0.040 |
Why?
|
| Receptor, Anaphylatoxin C5a | 1 | 2017 | 3 | 0.040 |
Why?
|
| Antigen-Presenting Cells | 1 | 2017 | 24 | 0.040 |
Why?
|
| Complement Activation | 1 | 2017 | 24 | 0.040 |
Why?
|
| Femur | 1 | 2017 | 132 | 0.030 |
Why?
|
| Autoantibodies | 1 | 2017 | 114 | 0.030 |
Why?
|
| Immunoglobulin G | 1 | 2017 | 184 | 0.030 |
Why?
|
| Muscle Hypotonia | 1 | 2016 | 22 | 0.030 |
Why?
|
| Failure to Thrive | 1 | 2016 | 19 | 0.030 |
Why?
|
| Facies | 1 | 2016 | 35 | 0.030 |
Why?
|
| Lumbar Vertebrae | 1 | 2017 | 99 | 0.030 |
Why?
|
| Agammaglobulinemia | 1 | 2015 | 9 | 0.030 |
Why?
|
| Treatment Outcome | 2 | 2016 | 5203 | 0.030 |
Why?
|
| Syndrome | 1 | 2016 | 239 | 0.030 |
Why?
|
| T-Lymphocytes | 1 | 2017 | 329 | 0.030 |
Why?
|
| Organ Size | 1 | 2015 | 223 | 0.030 |
Why?
|
| Anticonvulsants | 1 | 2016 | 125 | 0.030 |
Why?
|
| Hemoglobins | 1 | 2015 | 106 | 0.030 |
Why?
|
| Bone Density | 1 | 2017 | 386 | 0.030 |
Why?
|
| Registries | 1 | 2017 | 527 | 0.030 |
Why?
|
| Prevalence | 1 | 2017 | 960 | 0.030 |
Why?
|
| Patient Compliance | 1 | 2015 | 230 | 0.030 |
Why?
|
| Disease Management | 1 | 2015 | 175 | 0.030 |
Why?
|
| Intermediate Filaments | 1 | 2013 | 5 | 0.030 |
Why?
|
| Adherens Junctions | 1 | 2013 | 4 | 0.030 |
Why?
|
| Cytokines | 1 | 2017 | 607 | 0.030 |
Why?
|
| Exome | 1 | 2013 | 46 | 0.030 |
Why?
|
| Nevus | 1 | 2013 | 16 | 0.030 |
Why?
|
| Mosaicism | 1 | 2013 | 18 | 0.030 |
Why?
|
| Gene Expression | 1 | 2016 | 612 | 0.030 |
Why?
|
| Hair Follicle | 1 | 2013 | 34 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 2013 | 236 | 0.030 |
Why?
|
| Cell Differentiation | 1 | 2015 | 648 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2017 | 1419 | 0.020 |
Why?
|
| Animals | 2 | 2017 | 13141 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2016 | 2396 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2010 | 176 | 0.020 |
Why?
|
| Genetic Testing | 1 | 2010 | 119 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2020 | 6190 | 0.020 |
Why?
|
| Base Sequence | 1 | 2010 | 653 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2010 | 576 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2010 | 795 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2015 | 1529 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2010 | 508 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2013 | 1612 | 0.020 |
Why?
|
| Mice | 1 | 2017 | 5673 | 0.020 |
Why?
|
| Prognosis | 1 | 2010 | 1963 | 0.010 |
Why?
|